Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well telotristat ethyl works in promoting weight stability in
patients with pancreatic adenocarcinoma that has come back and spread to other places in the
body. Telotristat ethyl may decrease bowel movements which may make patients gain weight.
Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.